Matthew Herper covers medical innovation — both its promise and its perils. SAN FRANCISCO — On Sunday, Alnylam, the gene-silencing company that notched one gigantic accomplishment after another over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results